DNA vaccines for non-infectious diseases: New treatments for tumour and allergy

Expert Opinion on Biological Therapy

Volumn 3, Issue 4, 2003, Pages 627-638

  Leitner, Wolfgang W ^b   Thalhamer, Josef ^a  

^a UNIVERSITY OF SALZBURG   (Austria)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Allergy; Cancer; DNA recoding harmonisation; DNA vaccines; Electrovaccination; Genetic immunisation; Heterologous prime boost regimen; Hypoallergens; Replicase base DNA vaccines; Th1 Th2 response

Indexed keywords

ART V1 DNA VACCINE; BET V1 PROTEIN; BETA GALACTOSIDASE; CANCER VACCINE; CYTOKINE; DNA VACCINE; DOUBLE STRANDED RNA; GENE PRODUCT; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G2A; MATRIX METALLOPROTEINASE; MESSENGER RNA; PLASMID DNA; POLLEN ANTIGEN; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2; RNA DIRECTED RNA POLYMERASE; SALMONELLOSIS VACCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ALLERGY; ANIMAL CELL; ANTIGEN BINDING; CANCER ADJUVANT THERAPY; CELL SPECIFICITY; CHEMICAL MODIFICATION; CPG ISLAND; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG POTENCY; DRUG SAFETY; DRUG USE; FRAGMENTATION REACTION; GENE IDENTIFICATION; GENE TARGETING; GENE THERAPY; GENETIC ENGINEERING; HELPER CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL RESEARCH; MOUSE; NONHUMAN; REVIEW; TH1 CELL; TUMOR IMMUNITY; UBIQUITINATION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ALLERGENS; ANIMALS; CYTOKINES; HUMANS; HYPERSENSITIVITY; IMMUNIZATION SCHEDULE; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; VACCINES, DNA;

ANIMALIA;

EID: 0038603189     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.3.4.627     Document Type: Review

References (111)

1. ULMER JB, DONNELLY JJ, PARKER SE et al: Heterologous protection against influenza by injection of DNA encoding a viral protein. Science (1993) 259:1745-1749. First publication demonstrating induction of CTL and antiviral efficacy of DNA vaccines.
2. TANG DC, DEVIT M, JOHNSTON SA: Genetic immunization is a simple method for eliciting an immune response. Nature (1992) 356:152-154. Proof-of-principle of DNA vaccines - the first paper.
3. GURUNATHAN S, KLINMAN DM, SEDER RA: DNA vaccines: immunology, application, and optimization. Ann. Rev. Immunol. (2000) 18:927-974. Instructive review for beginners in the field of DNA vaccines.
4. LEITNER WW, YING H, RESTIFO NP: DNA and RNA-based vaccines: principles, progress and prospects. Vaccine (1999) 18:765-777.
5. LEITNER WW, HAMMERL P, THALHAMER J: Nucleic acid for the treatment of cancer: genetic vaccines and DNA adjuvants. Curr. Pharm. Des. (2001) 7:1641-1667.
6. WAISMAN A, RUIZ PJ, HIRSCHBERG DL et al.: Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity. Nat. Med. (1996) 2:899-905.
7. LOBELL A, WEISSERT R, STORCH MK et al.: Vaccination with DNA encoding an immunodominant myelin basic protein peptide targeted to Fc of immunoglobulin G suppresses experimental autoimmune encephalomyelitis. J. Exp. Med. (1998) 187:1543-1548.
8. HSU CH, CHUA KY, TAO MH et al.: Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nat. Med. (1996) 2:540-544. First paper demonstrating the antiallergic effect of DNA vaccines with a clinically relevant mite allergen.
9. RAZ E, TIGHE H, SATO Y et al.: Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc. Natl. Acad. Sci. USA (1996) 93:5141-5145. First paper demonstrating the antiallergic effect of DNA vaccines with a model antigen.
10. GREGORIADIS G: DNA vaccines: a role for liposomes. Curr. Opin. Mol. Ther. (1999) 1:39-42.
11. NICHOLS WW, LEDWITH BJ, MANAM SV et al.: Potential DNA vaccine integration into host cell genome. Ann. NY Acad. Sci. (1995) 772:30-39.
12. MARTIN T, PARKER SE, HEDSTROM R et al: Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. Hum. Gene Ther. (1999) 10:759-768.
13. MANAM S, LEDWITH BJ, BARNUM AB et al.: Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA. Intervirology (2000) 43:273-281.
14. WHALEN RG: DNA vaccines for emerging infectious diseases: what if? Emerg. Infect. Dis. (1996) 2:168-175.
15. BERGMANN-LEITNER ES, DUNCAN EH, LEITNER WW: Identification and targeting of tumor escape mechanisms: the key for the cure? Curr. Pharm. Des. (2003) (In Press).
16. FUCHS EJ, MATZINGER P: Is cancer dangerous to the immune system? Semin. Immunol. (1996) 8:271-280. Discusses a model of how the immune system recognises or ignores transformed cells.
17. MUNOZ N, BOSCH FX: The causal link between HPV and cervical cancer and its implications for prevention of cervical cancer. Bull. Pan. Am. Health Org. (1996) 30:362-377.
18. GOEDERT JJ, VITALE F, LAURIA C et al.: Risk factors for classical Kaposi's sarcoma. J. Natl. Cancer Inst. (2002) 94:1712-1718.
19. MILAN G, ROSATO A, ZAMBON A et al.: DNA immunization in mice against virusinduced tumor antigens. Adv. Exp. Med. Biol. (1998) 451:311-314.
20. DONNELLY JJ, MARTINEZ D, JANSEN KU et al.: Protection against papillomavirus with a polynucleotide vaccine. J. Infect. Dis. (1996) 173:314-320.
21. LEACHMAN SA, SHYLANKEVICH M, SLADE MD et al.: Ubiquitin-fused and/or multiple early genes from cottontail rabbit papillomavirus as DNA vaccines. J. Virol. (2002) 76:7616-7624.
22. TOULOUKIAN CE, LEITNER WW, SCHNUR RE et al.: Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1. J. Immunol. (2003) 170:1579-1585.
23. ROMAGNOLI P, HUDRISIER D, VAN MEERWIJK JP: Preferential recognition of self antigens despite normal thymic deletion of CD4(+)CD25(+) regulatory T cells. J. Immunol. (2002) 168:1644-1648.
24. LEITNER WW: Myth, menace or medical blessing? The clinical potential and problems of genetic vaccines. Expert Opin. Biol. Ther. (2003) 3(1):14.
25. TIMMERMAN JM, SINGH G, HERMANSON G et al.: Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res. (2002) 62:5845-5852.
26. CONRY RM, CURIEL DT, STRONG TV et al.: Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin. Cancer Res. (2002) 8:2782-2787.
27. YING H, ZAKS T, WANG RF et al.: Cancer therapy using a self-replicating RNA vaccine. Nat. Med. (1999) 5:823-827.
28. GILBOA E, NAIR SK, LYERLY HK: Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol. Immunother. (1998) 46:82-87.
29. DAVIS HL: CpG motifs for optimization of DNA vaccines. Dev. Biol. (Basel) (2000) 104:165-169.
30. GREGORY CD: CD14-dependent clearance of apoptotic cells: relevance to the immune system. Curr. Opin. Immunol. (2000) 12:27-34.
31. RESTIFO NP: Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity. Curr. Opin. Immunol. (2000) 12:597-603. This review discusses different aspects of apoptosis and what role programmed cell death could play in the efficacy of vaccines.
32. CHATTERGOON MA, KIM JJ, YANG JS et al.: Targeted antigen delivery to antigenpresenting cells inducing dendritic cells by engineered Fas-mediated apoptosis. Nat. Biotechnol. (2000) 18:974-979.
33. SASAKI S, AMARA RR, ORAN AE et al.: Apoptosis-mediated enhancement of DNA-raised immune responses by mutant caspases. Nat. Biotechnol. (2001) 19:543-547.
34. LEITNER WW, YING H, DRIVER DA et al.: Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res. (2000) 60:51-55.
35. SCHLESINGER S: Alphavirus vectors: development and potential therapeutic applications. Exp. Opin. Biol. Ther. (2001) 1:177-191.
36. LEITNER WW, HWANG LN, DE VEER MJ et al.: Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat. Med. (2003) 9:33-39.
37. KIBLER KV, SHORS T, PERKINS KB et al.: Double-stranded RNA is a trigger for apoptosis in vaccinia virus-infected cells. J. Virol. (1997) 71:1992-2003.
38. COLMENERO P, CHEN M, CASTANOSVELEZ E et al: Immunotherapy with recombinant SFV-replicons expressing the PS15A tumor antigen or IL-12 induces tumor regression. Int. J. Cancer (2002) 98:554-560.
39. CHENG WF, HUNG CF, HSU KF et al.: Cancer immunotherapy using Sindbis virus replicon partides encoding a VP22-antigen fusion. Hum. Gene Ther. (2002) 13:553-568.
40. IRVINE KR, CHAMBERLAIN RS, SHULMAN EP et al.: Enhancing efficacy of recombinant anticancer vaccines with prime/ boost regimens that use two different vectors. J. Natl. Cancer Inst. (1997) 89:1595-1601.
41. HILL AV, REECE W, GOTHARD P et al.: DNA-based vaccines for malaria: a heterologous prime-boost immunisation strategy. Dev. Biol. (Basel) (2000) 104:171-179.
42. MCSHANE H, BROOKES R, GILBERT SC et al.: Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect. Immun. (2001) 69:681-686.
43. SCHNEIDER J, GILBERT SC, HANNAN CM et al.: Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunol. Rev. (1999) 170:29-38.
44. GONZALO RM, DEL REAL G, RODRIGUEZ JR et al.: A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. Vaccine (2002) 20:1226-1231.
45. NYIKA A, BARBET AF, BURRIDGE MJ et al.: DNA vaccination with map 1 gene followed by protein boost augments protection against challenge with Cowdria ruminantium, the agent of heartwater. Vaccine (2002) 20:1215-1225.
46. AMARA RR, VILLINGER F, ALTMAN JD et al.: Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Vaccine (2002) 20:1949-1955.
47. PASQUINI S, PERALTA S, MISSIAGLIA E et al.: Prime-boost vaccines encoding an intracellular idiotype/GM-CSF fusion protein induce protective cell-mediated immunity in murine pre-B cell leukemia. Gene Ther. (2002) 9:503-510.
48. LEITNER WW, SEGUIN MC, BALLOU WR et al.: Immune responses induced by intramuscular or gene gun injection of protective deoxyribonucleic acid vaccines that express the circumsporozoite protein from Plasmodium berghei malaria parasites. J. Immunol. (1997) 159:6112-6119.
49. HAYNES JR, MCCABE DE, SWAIN WF et al.: Particle-mediated nucleic acid immunization. J. Biotechnol. (1996) 44:37-42.
50. PORGADOR A, IRVINE KR, IWASAKI A et al.: Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J. Exp. Med. (1998) 188:1075-1082. The authors demonstrate how the transfection of a small number of dendritic cells in the skin by the gene gun is sufficient to account for the strong immune response induced with this delivery method. They also describe the adjuvant-effect the gene gun delivery has in terms of dendritic cell activation.
51. FELTQUATE DM, HEANEY S, WEBSTER RG et al.: Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J. Immunol. (1997) 158:2278-2284.
52. WEISS R, LEITNER WW, SCHEIBLHOFER S et al.: Genetic vaccination against malaria infection by intradermal and epidermal injections of a plasmid containing the gene encoding the Plasmodium berghei circumsporozoite protein. Infect. Immun. (2000) 68:5914-5919 (MEDLINE record in process).
53. WEISS R, SCHEIBLHOFER S, FREUND J et al.: Gene gun bombardment with gold particles displays a particular Th2-promoting signal that over-rules the Th1-inducing effect of immunostimulatory CpG motifs in DNA vaccines. Vaccine (2002) 20:3148-3154.
54. HOCHREITER R, HARTL A, FREUN DJ et al: The influence of CpG motifs on a protein or DNA-based Th2-type immune response against major pollen allergens Bet v 1a, Ph1 p 2 and Escherichia coli-derived β-galactosidase. Int. Arch. Allergy Immunol. (2001) 124:406-410.
55. CIERNIK IF, BERZOFSKY JA, CARBONE DP: Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J. Immunol. (1996) 156:2369-2375.
56. BRISTOL JA, ORSINI C, LINDINGER P et al.: Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization. Cell Immunol. (2000) 205:73-83.
57. FOMSGAARD A, NIELSEN HV, KIRKBY N et al.: Induction of cytotoxic T-cell responses by gene gun DNA vaccination with minigenes encoding influenza A virus HA and NPCTL-epitopes. Vaccine (1999) 18:681-691.
58. FENSTERLE J, GRODE L, HESS J et al.: Effective DNA vaccination against listeriosis by prime/boost inoculation with the gene gun. J. Immunol. (1999) 163:4510-4518.
59. TUTING T, GAMBOTTO A, DELEO A et al.: Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Ther. (1999) 6:73-80.
60. YOSHIDA A, NAGATA T, UCHIJIMA M et al.: Advantage of gene gun-mediated over intramuscular inoculation of plasmid DNA vaccine in reproducible induction of specific immune responses. Vaccine (2000) 18:1725-1729.
61. ROY MJ, WU MS, BARR LJ et al.: Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine (2000) 19:764-778.
62. SCHEIBLHOFER S, CHEN D, WEISS R et al.: Removal of the circumsporozoite protein (CSP) glycosylphosphatidylinositol signal sequence from a CSP DNA vaccine enhances induction of CSP-specific Th2 type immune responses and improves protection against malaria infection. Eur. J. Immunol. (2001) 31:692-698.
63. SPELLBERG B: The cutaneous citadel: a holistic view of skin and immunity. Life Sci. (2000) 67:477-502.
64. MCALLISTER DV, ALLEN MG, PRAUSNITZ MR: Microfabricated microneedles for gene and drug delivery. Ann. Rev. Biomed. Eng. (2000) 2:289-313.
65. BRAMSON J, DAYBALL K, EVELEGH C et al.: Enabling topical immunization via microporation: a novel method for pain-free and needle-free delivery of adenovirus-based vaccines. Gene Ther. (2003) 10:251-260.
66. TREZISE AE: In vivo DNA electrotransfer. DNA Cell Biol. (2002) 21:869-877.
67. TAMURA T, SAKATA T: Application of in vivo electroporation to cancer gene therapy. Curr. Gene Ther. (2003) 3:59-64.
68. KALAT M, KUPCU Z, SCHULLER S et al.: In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model. Cancer Res. (2002) 62:5489-5494.
69. BUREAU MF, GEHL J, DELEUZE V et al.: Importance of association between permeabilization and elecrophoretic forces for intramuscular DNA elecrotransfer. Biochim. Biophys. Acta (2000) 1474:353-359.
70. PERTL U, WODRICH H, RUEHLMANN JM et al.: Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma. Blood (2003) 101:649-654.
71. VINDURAMPULLE CJ, ATTRIDGE SR: Impact of vector priming on the immunogenicity of recombinant Salmonella vaccines. Infect. Immun. (2003) 71:287-297.
72. LI S, ZHANG X, XIA X et al.: Intramuscular electroporation delivery of IFN-alpha gene therapy for inhibition of tumor growth located at a distant site. Gene Ther. (2001) 8:400-407.
73. LEE SC, WU CJ, WU PY et al.: Inhibition of established subcutaneous and metastatic murine tumors by intramuscular electroporation of the interleukin-12 gene. J. Biomed. Sci. (2003) 10:73-86.
74. HANNA E, ZHANG X, WOODLIS J et al.: Intramuscular electroporation delivery of IL-12 gene for treatment of squamous cell carcinoma located at distant site. Cancer Gene Ther. (2001) 8:151-157.
75. BRAMSON JL, DAYBALL K, HALL JR et al.: Super-activated interferon-regulatory factors can enhance plasmid immunization. Vaccine (2003) 21:1363-1370.
76. SLINGLUFF CL JR, COLELLA TA, THOMPSON L et al.: Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunol. Immunother. (2000) 48:661-672.
77. SU JM, WEI YQ, TIAN L et al.: Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2. Cancer Res. (2003) 63:600-607.
78. LOU YY, WEI YQ, YANG L et al.: Immunogene therapy of tumors with a vaccine based on the ligand-binding domain of chicken homologous integrin beta3. Immunol. Invest. (2002) 31:51-69.
79. CICHON T, JAMROZY L, GLOGOWSKA J et al.: Electrotransfer of gene encoding endostatin into normal and neoplastic mouse tissues: inhibition of primary tumor growth and metastatic spread. Cancer Gene Ther. (2002) 9:771-777.
80. BABIUK LA, PONTAROLLO R, BABIUK S et al.: Induction of immune responses by DNA vaccines in large animals. Vaccine (2003) 21:649-658.
81. SINGH VK, MEHROTRA S, AGARWAL SS: The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol. Res. (1999) 20:147-161.
82. PARRONCHI P, MAGGI E, ROMAGNANI S: Redirecting Th2 responses in allergy. Curr. Top. Microbiol. Immunol. (1999) 238:27-56.
83. DE VRIES JE, CARBALLIDO JM, AVERSA G: Receptors and cytokines involved in allergic TH2 cell responses. J. Allergy Clin. Immunol. (1999) 103:S492-496.
84. HARTL A, KIESSLICH J, WEISS R et al.: Immune responses after immunization with plasmid DNA encoding Bet v 1, the major allergen of birch pollen. J. Allergy Clin. Immunol. (1999) 103:107-113. Chracterisation of the immune response against the clinically relevant allergen Bet v1 induced by intradermal needle injection of high doses of a DNA vaccine and modulations via CpG motifs.
85. ADEL-PATIENT K, CREMINON C, BOQUET D et al.: Genetic immunisation with bovine beta-lactoglobulin cDNA induces a preventive and persistent inhibition of specific anti-BLG IgE response in mice. Int. Arch. Allergy Immunol. (2001) 126:59-67.
86. JACQUET A, MAGI M, HAUMONT M et al.: Absence of immunoglobulin E synthesis and airway eosinophilia by vaccination with plasmid DNA encoding ProDer p 1. Clin. Exp. Allergy (2003) 33:218-225.
87. WOLFOWICZ CB, HUANGFU T, CHUA KY: Expression and immunogenicity of the major house dust mite allergen Der p I following DNA immunization. Vaccine (2003) 21:1195-1204.
88. KWON SS, KIM N, YOO TJ: The effect of vaccination with DNA encoding murine T-cell epitopes on the Der p 1 and 2 induced immunoglobulin E synthesis. Allergy (2001) 56:741-748.
89. PENG HJ, SU SN, CHANG ZN et al.: Induction of specific Th1 responses and suppression of IgE antibody formation by vaccination with plasmid DNA encoding Der f11. Vaccine (2002) 20:1761-1768.
90. ROY K, MAO HQ, HUANG SK et al.: Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med. (1999) 5:387-391. Interesting approach offering alternative approaches for DNA vaccines, especially with respect to food allergens.
91. HARTL A, KIESSLICH J, WEISS R et al.: Isoforms of the major allergen of birch pollen induce different immune responses after genetic immunization. Int. Arch. Allergy Immunol. (1999) 120:17-29.
92. MAECKER HT, HANSEN G, WALTER DM et al.: Vaccination with allergen-IL-18 fusion DNA protects against, and reverses established, airway hyperreactivity in a murine asthma model. J. Immunol. (2001) 166:959-965.
93. SUDOWE S, MONTERMANN E, STEITZ J et al.: Efficacy of recombinant adenovirus as vector for allergen gene therapy in a mouse model of Type I allergy. Gene Ther. (2002) 9:147-156.
94. JILEK S, BARBEY C, SPERTINI F et al.: Antigen-independent suppression of the allergic immune response to bee venom phospholipase A(2) by DNA vaccination in CBA/J mice. J. Immunol. (2001) 166:3612-3621. Demonstration of the antigen-nonspecific protective and therapeutic effect of plasmid DNA.
95. KRIEG AM: CpG motifs in bacterial DNA and their immune effects. Ann. Rev. Immunol. (2002) 20:709-760. Recommendable review dealing with the various aspects of immunostimulatory DNA sequences.
96. HILLER R, LAFFER S, HARWANEGG C et al.: Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment. FASEB J. (2002) 16:414-416.
97. SLATER JE, PAUPORE E, ZHANG YT et al.: The latex allergen Hev b 5 transcript is widely distributed after subcutaneous injection in BALB/c mice of its DNA vaccine. J. Allergy Clin. Immunol. (1998) 102:469-475. A critical article indicating a body-wide distribution of DNA vaccines.
98. MASSAER M, MAZZU P, HAUMONT M et al.: High-level expression in mammalian cells of recombinant house dust mite allergen ProDer p 1 with optimized codon usage. Int. Arch. Allergy Immunol. (2001) 125:32-43.
99. HIMLY M, JAHN-SCHMID B, DEDIC A et al.: Art v 1, the major allergen of mugwort pollen, is a modular glycoprotein with a defensin-like and a hydroxyproline-rich domain. FASEB J. (2003) 17:106-108.
100. BAUER R, HIMLY M, DEDIC A et al.: Optimization of codon usage is required for effective generic immunization against Art v 1, the major allergen of mugwort pollen. Allergy (2003) (In Press). This paper demonstrates the striking effect of the codon usage on the immunogenicity of allergen DNA vaccines.
101. WEISS R, DURNBERGER J, MOSTBOCK S et al.: Improvement of the immune response against plasmid DNA encoding OspC of Borrelia by an ER-targeting leader sequence. Vaccine (1999) 18:815-824.
102. XIANG Z, ERTL HC: Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity (1995) 2:129-135.
103. GREGORIADIS G, SAFFIE R, DE SOUZA JB: Liposome-mediated DNA vaccination. FEBS Lett. (1997) 402:107-110.
104. NAKAMURA Y, GOJOBORI T, IKEMURA T: Codon usage tabulated from international DNA sequence databases: status for the year 2000. Nucleic Acids Res. (2000) 28:292.
105. LIU WJ, ZHAO KN, GAO FG et al.: Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. Vaccine (2001) 20:862-869.
106. LIUW J, GAO F, ZHAO KN et al.: Codon modified human papillomavirus Type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity. Virology (2002) 301:43-52.
107. FERREIRA F, EBNER C, KRAMER B et al.: Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy. FASEB J. (1998) 12:231-242. Creation of hypoallergenic recombinant allergens for specific immunotherapy.
108. HOCHREITER R, STEPANOSKA T, FERREIRA F et al.: Prevention of Allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch pollen allergen. Eur. J. Immunol. (2003) 33:1667-1676. Novel approaches for the development of safe DNA vaccines for allergy protection and treatment.
109. VRTALA S, AKDIS CA, BUDAK F et al.: T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodiess. J. Immunol. (2000) 165:6653-6659.
110. RODRIGUEZ F, ZHANG J, WHITTON JL: DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J. Virol. (1997) 71:8497-8503.
111. HARTLA, WEISS R, HOCHREITER R et al.: DNA vaccines for allergy treatment. Methods (2003) (In Press). A 'cookbook' for researchers planning to work with allergen DNA vaccines.